Around $15M Bet On Taysha Gene Therapies? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Portfolio Pulse from Lisa Levin
Insiders at Taysha Gene Therapies, Amarin Corporation, Rapid Micro Biosystems, and Indaptus Therapeutics have recently made significant purchases of their companies' stocks. Taysha Gene Therapies reported initial clinical data from the first adult Rett Syndrome patient dosed in the REVEAL Phase 1/2 trial and announced $150 million private placement financing. Amarin posted a profit for the second quarter. Rapid Micro Biosystems and Indaptus Therapeutics posted narrower-than-expected quarterly losses.
August 17, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin Corporation's President and CEO Patrick Holt acquired a total of 300,000 shares at an average price of $1.04, spending around $312,315. The company posted a profit for the second quarter.
The insider purchase by the CEO, along with the company's Q2 profit, could signal a positive outlook and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Indaptus Therapeutics' 10% owner Glen R Anderson acquired a total of 103,352 shares at an average price of $2.09, spending $216,388. The company posted a narrower-than-expected quarterly loss.
The significant insider purchase, along with the better-than-expected quarterly results, could signal a positive outlook and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Rapid Micro Biosystems' President and CEO Robert G. Spignesi, Jr. acquired a total of 20,000 shares at an average price of $0.97, costing around $19,488. The company posted a narrower-than-expected quarterly loss.
The CEO's purchase of shares, along with the company's better-than-expected quarterly results, could indicate a positive outlook and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Taysha Gene Therapies' 10% owner Paul Manning acquired a total of 16,466,667 shares at an average price of $0.90, costing around $14.82 million. The company reported initial clinical data from the first adult Rett Syndrome patient dosed in the REVEAL Phase 1/2 trial and announced $150 million private placement financing.
The significant insider purchase, combined with the positive clinical data and financing announcement, could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100